ALERTS, CHARTS, & HOT STOCKS

[Singhania]

Analysts Think $CRDL is Undervalued

Last week, Canaccord Genuity lifted the PT to $8 from $6 on Cardiol Therapeutics Inc (NASDAQ: CRDL) – Potential gain of 260% from CMP.

Analyst Vernon Bernardino of H.C. Wainwright & Co reiterated their Buy rating and with a PT of $9.

Moreover, Joe Gantoss of Chimera Research Group says he won’t be surprised to see Cardiol’s price break past the 3-year high at $4.96 if the recurrent pericarditis data show a clear success and open the path to move to the next stage with Phase 3 trial.

$RSLS $MRNA $NVAX $INSM $KTRA $VTYX $SCPX